Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Randomized Controlled Trial - Top-Institutions - MDSpire

Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Randomized Controlled Trial

  • By

  • Per Åkesson

  • Lisa Mellhammar

  • Magnus Rasmussen

  • Malin Inghammar

  • Sara Jesperson

  • Fredrik Månsson

  • Elin Economou Lundeberg

  • John Walles

  • Martin Wallberg

  • Attila Frigyesi

  • Adam Linder

  • April 24, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Jewish Health
    National Jewish Health

    Denver, CO

    Key Differentiators

    • Pulmonology
    • Immunology
    • Critical Care Medicine

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Pulmonology
    • Critical Care Medicine
    • Infectious Diseases

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Pulmonology
    • Critical Care Medicine
    • Translational Medicine

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Pulmonology
    • Critical Care Medicine
    • Immunology

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Pulmonology
    • Critical Care Medicine
    • Infectious Diseases

Original Source(s)

Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Randomized Controlled Trial

  • by Per Åkesson, Lisa Mellhammar, Magnus Rasmussen, Malin Inghammar, Sara Jesperson, Fredrik Månsson, Elin Economou Lundeberg, John Walles, Martin Wallberg, Attila Frigyesi, Adam Linder

  • April 24, 2025

Related Content

Early ICU Rehab Backed, With Caveats

Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

Acute liver failure and secondary TMA-like phenomenon following SARS-CoV-2 and Mycoplasma pneumoniae co-detection in a child: a case report